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http:WHAT THIS PAPER ADDS
This study adds new markers of renal function and renal volume, which can easily be assessed during follow up
to demonstrate renal impairment. The results from this study conﬁrm that FEVAR and BEVAR are durable op-
tions for the treatment of complex aortic aneurysms and are associated with a low renal morbidity rate, without
any differences between these devices.Objective: The purpose of this study was to analyze immediate and long-term renal outcomes (renal function and
renal events) after fenestrated (FEVAR) and branched endovascular aortic aneurysm repair (BEVAR).
Methods: All FEVAR and BEVAR performed between October 2004 and October 2012 were included in this study.
Post-operative acute renal failure (ARF) was deﬁned according to the RIFLE criteria. Renal volume (calculated
with a 3D workstation) and estimated glomerular ﬁltration rate (GFR) (estimated with the Modiﬁcation of Diet in
Renal Disease [MDRD] formula) were evaluated before the procedure, before discharge, 12 months after, and
yearly thereafter. Renal stent occlusion, dissection, fracture, stenosis, kink, renal stent related endoleak, and renal
stent secondary intervention were all considered “renal composite events” and analyzed. A time to event analysis
was performed for renal events and secondary renal interventions.
Results: 225 patients were treated with FEVAR and BEVAR. Renal target vessels (n ¼ 427) were perfused by
fenestrations (n ¼ 374), or branches (n ¼ 53). Median follow up was 3.1 years (2.9e3.3 years). Technical success
was achieved in 95.5% of patients. Post-operative ARF was seen in 64 patients (29%). Mean total renal volume
and eGFR at 1 year, 2 year, and 3 year follow up were signiﬁcantly lower when compared with pre-operative
levels (after BEVAR and FEVAR); the decrease at 3 years was 14.8% (6.7%; 22.2%) (p ¼ .0006) for total renal
volume and 14.3% (3.1%; 24.3%) (p ¼ .02) for eGFR. The 30 day and 5 year freedom from renal composite event
was 98.6% (95.8e99.6%) and 84.5% (76.5e89.9%) after FEVAR and BEVAR (NS). The 30 day and 5 year freedom
from renal occlusion was 99.5% (96.7e99.9%) and 94.4% (89.3e97.1%) after FEVAR and BEVAR (NS).
Conclusion: FEVAR and BEVAR are durable options for the treatment of complex aortic aneurysms and are
associated with low renal morbidity, without differences between devices types. The clinical impact of decreasing
renal volume over time in these patients is yet to be fully understood.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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The ﬁrst reports of endovascular treatment of complex
juxtarenal/pararenal aortic aneurysms (JR-PRAA) and
thoraco-abdominal aortic aneurysms (TAAA) were pub-
lished by Faruqui et al. in 19991 and Chuter et al. in 2001.2
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//dx.doi.org/10.1016/j.ejvs.2015.04.011clinical use, and a recent review comparing endovascular
and open repair3 of complex aneurysms reported a 2.4% 30
day mortality rate after fenestrated endovascular repair
(FEVAR) versus 3.4% after open repair and 5.3% following
chimney repair.
Post-operative renal impairment is one of the most
frequent major complications associated with complex
aneurysm treatment using any modality. Nordon et al.4
described in their systematic review an incidence of early
transient renal failure of 15% following FEVAR compared
with 20% after open repair. Mid- and long-term renal out-
comes after complex endovascular repair are associated
with “branch instability” as deﬁned by Mastracci et al5:
branch occlusion, device migration affecting a branch,
branch related growth, or the need for any secondary
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impairment are used in the literature describing outcomes
for fenestrated repair, it is difﬁcult to perform an effective
comparison across all reports. The purpose of this study was
to analyze immediate and long-term renal outcomes after
complex endovascular repair performed in a high volume
center.
MATERIAL AND METHODS
Study population
All complex endovascular repairs (including both FEVAR
[fenestrated endovascular aortic aneurysm repair] and
BEVAR [branched endovascular repair]) performed in a
single institution between October 2004 and October 2012
were included in this study. Ruptured aneurysms and acute
aortic dissections were excluded.
All patients were treated by the same group of vascular
surgeons at a single high volume academic center. In order
to have a follow up  12 months, patients treated after
October 2012 were not included. All endovascular pro-
cedures were performed with fenestrated or branched
endografts manufactured by Cook Medical (Bloomington,
IN, USA). The FEVAR and BEVAR procedures were per-
formed with a mobile C-arm. In accordance with the liter-
ature,6,7 iso-osmolar iodixanol contrast media (Visipaque,
320 mg I/mL, GE Healthcare, Dublin, Ireland) was used
when the estimated glomerular ﬁltration rate (eGFR)
was< 60 mL/min/1.73 m2, and low osmolar iohexol
contrast media (Omnipaque, 300 mg I/mL, GE Healthcare)
in the remaining patients.
Patient data were prospectively collected in an electronic
database and electronic or paper medical records were also
reviewed retrospectively for the purpose of this study.
Baseline demographics and risk factors, including medica-
tions with renal impact and intra-operative contrast vol-
ume, were collected.Renal function
eGFR was determined using the abbreviated MDRD study
equation (eGFR mL/min/1.73 m2 ¼ 186  [serum
creatinine]1.154  [age]0.203  [0.704 if female]  [1.210
if African American]).8 The eGFR was calculated and
collected pre-operatively, on the ﬁrst post-operative day, on
the day of discharge, and yearly thereafter. Chronic kidney
disease (CKD) was deﬁned as eGFR < 60 mL/min/1.73 m2
based on the National Kidney Foundation/Kidney Disease
Outcome Quality Initiative (NKF/KDOQI).8 The RIFLE classi-
ﬁcation,9 based on eGFR evaluated 48e72 hours after the
procedure, was used for the post-operative diagnosis of
acute renal failure (ARF), deﬁned as an increase in eGFR of
at least 25%.Imaging analysis
Pre-operative multi-detector computed tomography
(MDCT) scans were obtained in all patients. A CT scan was
also performed at discharge, 12 months, and yearlythereafter. All CT scans analyzed in this study were per-
formed during the standard follow up protocol after FEVAR/
BEVAR. Renal duplex imaging was also performed to sup-
plement data.
MDCT scans were loaded into a workstation (Aqua-
riusNET software, TeraRecon Inc., San Mateo, CA, USA) for
imaging analysis by one of the authors (T.M.G.). A stan-
dardized protocol for assessment was developed. The
longest cranio-caudal renal length was selected from the
three dimensional volume rendered reconstruction and
measured on both sides. Combined kidney length mea-
surements (mean renal length) were calculated for each
pair of kidneys. The volume of each kidney was calculated
by the following method: a semi-automated post-process-
ing treatment extracted the renal contour. The pelvicalyceal
systems, fat and vessels in the renal sinus, and renal cysts
were excluded by manual correction on multiplanar views
in case they had been automatically included. Then, the
renal volume was automatically measured (in cm3). Com-
bined kidney volumes (sum of right and left volumes) were
also calculated for each pair of kidneys. Intra- and inter-
observer differences were analyzed using the intraclass
correlation coefﬁcient (ICC). Ten patients included in a
previous study with similar analysis were analyzed three
times by two physicians. No signiﬁcant intra- or inter-
observer variation were observed (volume: ICC ¼ 0.999
[CI 95%, 0.998e1.000] [p < .000]; length: ICC ¼ 0.991 [CI
95%, 0.980e0.996] [p < .000]).
The renal artery angles were measured by the method
described by Conway et al.10: a semi-automated centerline
was generated from the aortic bifurcation to the level of the
diaphragm. The centerline was assessed with multiplanar
reconstruction views perpendicular to the centerline of
ﬂow. A positive renal artery implantation angle (RAIA) was
deﬁned as an angle above the horizontal plane perpendic-
ular to the aortic centerline of ﬂow at the mid level of the
renal ostia. A quantitative angular measurement for the
RAIA was taken using the angular measurement tool pro-
vided in the AquariusNET software. The process was
repeated for each renal artery, stented or involved in the
graft including accessory renal arteries, pre-operatively and
at each follow up. Accessory renal arteries were measured
and recorded only if they were included in the device.
Renal outcome events were assessed using the MDCT
scan and were complemented with duplex ultrasound.
Duplex ultrasound criteria applied were deﬁned by
Mohabbat et al.11 and MDCT scan interpretation was based
on the methods described by Dowdall et al.12 Imaging
outcomes were deﬁned according to reporting standards13
and to modiﬁcations assessed by Mastracci et al.5 Renal
composite outcome included branch occlusion, in-stent
stenosis, stent kinking, stent fracture, and renal related
endoleak.Statistical analysis
Analyses were conducted using SAS software (SAS version
9.2, SAS Institute Inc., Cary, NC, USA).
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median (25the75th percentile), as appropriate. Categorical
variables are presented as absolute numbers and percent-
ages. The comparison of subjects with a fenestrated device
to subjects with a multi-branched device was performed
using the Student t or ManneWhitney U tests according to
normality assessed by the ShapiroeWilk test and using the
chi-square test or the Fisher exact test, as appropriate, for
proportions of categorical variables.
Longitudinal data (serum creatinine, eGFR, renal volumes
and lengths) were analyzed using repeated measures anal-
ysis of covariance (PROC MIXED) with time as a categorical
covariate (pre-operatively, at 1 year, 2 years, and 3 years of
follow up), and with a REPEATED statement for within pa-
tient correlation. Data were log-transformed because of
skewed distributions. The repeated measures covariance
structure was selected with likelihood ratio tests in case of
nested models or using the Bayesian Information Criterion
for non-nested models. Multivariate models were built by
ﬁrst including all predictors and then using a backward se-
lection to reduce the model. In case of a signiﬁcant inter-
action between two predictors, the two main effect terms
remained in the model, even if not signiﬁcant. Regression
underlying assumptions were visually inspected with re-
sidual plots. Inﬂuential observations were assessed using
Cook’s distance and leverage measure and removed from
the models to ensure that conclusions remained valid. Pa-
rameters of the models were tested with polynomial con-
trasts, and means and 95% conﬁdence intervals were
estimated using least square means.
Event free survival curves were estimated using the
KaplaneMeier method and compared using the log-rank
test. Median follow up time was estimated with the
reverse KaplaneMeier method. Univariate Cox analyses
were performed to identify independent predictors of event
(renal event e being censored at the time of death, death).
The log-linearity assumption for continuous variables and
the proportional hazard assumption were tested by
Kolmogorov-type supremum tests as implemented in the
PROC PHREG and visually inspected with residual plots. In
case of violation of the former assumption, the continuous
variable was dichotomized, the cut off value being visually
established and maximizing the Harrell c statistics (as a
measure of calibration) and the Kent and O’Quigley r2 (as a
measure of discrimination); in case of violation of the latter
assumption, a piecewise model was used to model the
hazard ratio as a step function of time. Since the main aim
of this article was to study the predictive value of type of
device, interactions between type of device and the other
covariates were systematically tested by comparing models
with interactions to models without interactions with like-
lihood ratio tests. Multivariate Cox models were built using
best subset selection, and selected using the Schwarz
Bayesian Criterion, Harrell c statistics, and Kent and
O’Quigley r2.
Logistic regression analysis was used to identify prog-
nostic factors of acute renal failure (ARF). The log linearity
assumption was tested by comparing a model with thecontinuous covariate with a model including a quadratic
component with a F test for nested models, and was
visually checked using spline functions plotting the
empirical logits against the considered covariate. In case
of rejection, the continuous variable was dichotomized so
as to maximize the area under the receiver operating
characteristic curve (c statistic). Again, interactions be-
tween type of device and the other covariates were
systematically tested by comparing models with in-
teractions to models without interactions with likelihood
ratio tests. Multivariate logistic models were chosen using
best subset selection, and selected using Schwarz’s
Bayesian Criterion, c statistics and p of the Hosmere
Lemeshow test.
A two-tailed type I error rate < .05 was considered for
statistical signiﬁcance.
RESULTS
Between October 2004 and October 2012, 225 patients met
the inclusion criteria. The cut off day for inclusion was
November 1, 2012. According to the modiﬁed Crawford
classiﬁcation, 21.8% of patients were classiﬁed as TAAA
types I, II, or III, 10.7% as TAAA types IV or V, and 67.5% as
JR-PRAA. The procedure technical failure rate was 2.7%.
Four patients died during the ﬁrst 24 hour post-operative
period, including one on-table rupture; four failed vessel
catheterizations occurred.
A total of 433 target renal vessels were incorporated in
the endovascular repair, including 374 renal fenestrations
(FEVAR group) and 53 renal branches (BEVAR group). In
86.9% of patients the bridging stent was a covered stent.
The median follow up (CI 95%) was 3.1 (2.9e3.3) years.
Both groups were comparable except for aortic aneurysm
diameter, previous aortic surgery, and pre-operative CKD.
Pre-operative renal measures and pre-operative renal
function were also comparable (Table 1).Mortality
A total of 67 deaths were reported during the study period.
The 30 day mortality rate was 6.2% (n ¼ 14) and three
additional patients suffered aneurysm related mortality
during follow up (Table 2). During follow up, 8 patients died
from cancer, 10 from cardiac failure, 5 from pulmonary
disease, and 15 from other medical diseases. This infor-
mation was collected prospectively in an electronic data-
base but was not available in 12 patients. There was no
evidence of procedure related issues at last follow up in
these 12 patients. Multivariate models showed that pe-
ripheral artery disease (PAD) (HR ¼ 4.245 [1.752; 10.283],
p ¼ .001) and left ventricular ejection fraction (LVEF) < 40%
(HR ¼ 5.830 [1.726; 19.693], p¼ .005) were associated with
an increased risk of death. In an equivalent multivariate
model, ARF before 6 months of follow up and post-
operative dialysis before 6 months of follow up were
associated with an increased risk of death (HR ¼ 4.497
[1.427; 14.176], p ¼ .01) and (OR ¼ 7.853 [2.874; 21.339],
p < .0001) respectively.
Table 1. Pre-operative demographics, risk factors and renal characteristics.
Pre-operative covariates Whole sample (n ¼ 225) Fenestrated (n ¼ 187) Multi-branched (n ¼ 38) p
Age at intervention (yrs) 70.5 (8.0) 70.7 (7.7) 69.8 (9.3) NS
Female 14 (6.2%) 10 (5.4%) 4 (10.5%) NS
BMI (kg/m2) 27.6 (4.6) 27.6 (4.6) 27.6 (4.7) NS
Diameter AA (mm) 60.4 (10.4) 59.4 (9.6) 65.4 (12.6) .008
Hypertension 178 (79.1%) 148 (79.1%) 30 (79.0%) NS
Hyperlipidemia 127 (56.4%) 107 (57.2%) 20 (52.6%) NS
Diabetes mellitus 47 (20.9%) 36 (19.3%) 11 (29.0%) NS
Smoker
No
Yes
Former
35 (15.6%)
62 (27.6%)
128 (56.9%)
28 (15.0%)
52 (27.8%)
107 (57.2%)
7 (18.4%)
10 (26.3%)
21 (55.3%)
NS
CAD 114 (50.7%) 96 (51.3%) 18 (47.4%) NS
COPD 95 (42.2%) 83 (44.4%) 12 (31.6%) NS
CKD 53 (23.6%) 38 (20.3%) 15 (39.5%) .01
LVEF < 40% 13 (5.8%) 13 (7.0%) 0 (0%) NS
Arrhythmia 33 (14.7%) 28 (15.0%) 5 (13.2%) NS
Stroke 28 (12.4%) 22 (11.8%) 6 (15.8%) NS
PAD 80 (35.6%) 63 (33.7%) 17 (44.7%) NS
Aortic surgery 55 (24.4%) 36 (19.3%) 19 (50.0%) < .0001
APT 178 (79.1%) 145 (77.5%) 33 (86.8%) NS
ACE inhibitors 86 (38.2%) 71 (38.0%) 15 (39.5%) NS
ARBs 67 (29.8%) 52 (27.8%) 15 (39.5%) NS
Diuretics 56 (24.9%) 48 (25.7%) 8 (21.1%) NS
Metformin 18 (8.0%) 13 (7.0%) 5 (13.2%) NS
Statins 163 (72.4%) 135 (72.2%) 28 (73.7%) NS
VKA 24 (10.7%) 18 (9.6%) 6 (15.8%) NS
Beta blockers 108 (48.0%) 87 (46.5%) 21 (55.3%) NS
ASA
2
3
4
5 (2.6%)
176 (92.2%)
10 (5.2%)
4 (2.5%)
147 (93.0%)
7 (4.4%)
1 (3.0%)
29 (87.9%)
3 (9.1%)
NS
Serum creatinine (mg/L) 11.0 (3.9) 10.8 (3.7) 11.9 (4.5) NS
MDRD (ml/min/1.73 m2)
Right renal volume (cm3)
77.0 (27.6)
185.8 (46.7)
77.7 (26.5)
185.6 (46.0)
73.5 (32.8)
190.0 (47.1)
NS
NS
Left renal volume (cm3) 183.8 (46.6) 182.7 (46.6) 190.0 (47.1) NS
Total renal volume (cm3) 365.9 (80.1) 364.1 (78.2) 376.5 (92.0) NS
Right renal length (mm)
Left renal length (mm)
114.6 (14.2)
113.1 (12.6)
114.3 (13.4)
113.3 (12.8)
116.7 (18.5)
112.1 (11.5)
NS
NS
Mean renal length (mm) 113.7 (11.3) 113.6 (11.1) 114.3 (12.6) NS
Right renal artery angulation () 30 (40; 16) 30 (40; 17) 21 (36; 0) NS
Left renal artery angulation () 28 (38; 13) 29 (38; 16) 27 (41; 45) NS
ACE ¼ angiotensin converting enzyme; APT ¼ antiplatelet therapy; ARBs ¼ angiotensin II receptor blockers; ASA ¼ American Society of
Anesthesiologists; BMI ¼ body mass index; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; COPD ¼ chronic obstruction
pulmonary disease; LFEV ¼ left ventricular ejection fraction; MDRD ¼ modiﬁcation of diet in renal disease; PAD ¼ peripheral artery
disease; VKA ¼ vitamin K antagonists.
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Post-operative ARF was seen in 64 patients (29%) and
hemodialysis was required in 13 (5.9%), and was perma-
nent in one. The new onset of hemodialysis rate was
0.44%. In patients requiring hemodialysis, four early
deaths occurred, two as a result of peri-renal hematoma,
one in the context of multi-organ failure, and the last one
as a consequence of a cardiac failure. Pre-operative CKD
was observed in six of 13 patients requiring hemodialysis.
Amongst them were the two patients who died following
peri-renal hematoma and the patient who required per-
manent hemodialysis. Post-operative ARF was observed in
four of 12 patients who had a dominant or single kidney. Itwas not associated with any renal adverse events in this
subgroup of patients.
At 1 year, 40.7% of patients who experienced post-
operative ARF had renal function similar to the baseline
level, and the remainder had a decrease in eGFR> 20%
compared with baseline.
During follow up four patients became dialysis depen-
dent. They all had pre-operative CKD and none experienced
renal events during follow up. In an adjusted model, CKD
was associated with an increased risk of ARF (HR ¼ 5.880
[2.745; 12.595], p < .0001). Other independent prognostic
covariates were pre-operative metformin treatment
(HR ¼ 3.974 [1.303; 12.122], p ¼ .02) and procedure time
Table 2. Description of 30 day mortality and aneurysm related mortality during follow up.
Patient Time of death Cause of death Renal complication Other complication
1 24 hour Cardiac failure e
2 24 hour Aortic rupture e
3 24 hour Iliac bypass rupture e
4 24 hour Right renal hematoma ARF
5 30 day Multi-organ failure ARF Cerebral ischemia
Iliac vein bleeding
6 30 day Multi-organ failure ARF þ HD Spinal cord ischemia
7 30 day Multi-organ failure ARF þ HD Cholesterol emboli
8 30 day Cardiac failure ARF þ HD
9 30 day Cerebral hemorrhage Endoleak I
Bilateral femoral hematoma
10 30 day Multi-organ failure ARF Multiple emboli
11 30 day Left renal artery rupture ARF þ HD
12 30 day Acute myocardial infarction ARF
13
14
30 day
30 day
Liver failure
Multi-organ failure
ARF
ARF þ HD
CT occlusion
Sepsis
15 Late Endograft infection
16 Late MI (type 3 endoleak and contained rupture) ARF
17 Late SMA occlusion ARF þ HD Left renal artery thrombosis
ARF ¼ acute renal failure; CT ¼ coeliac trunk; HD ¼ hemodialysis; MI ¼ myocardial infarction; SMA ¼ superior mesenteric artery.
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contrast media volume.
Fig. 1A shows the estimated means of eGFR (log trans-
formed) during follow up. In an adjusted multivariate mixed
model for log (eGFR) we found an eGFR decrease with time
(p < .0001), with 1, 2, and 3 year levels signiﬁcantly lower
than pre-operative levels (1, 2, and 3 year mean decrease
from pre-operative time estimated at 19.9% [13.1%; 26.2%],
p < .0001; 21.7% [14.0%; 28.7%], p < .0001; 14.3% [3.1%;
24.3%], p ¼ .02, respectively).
Renal morphology. In an adjusted multivariate mixed model
for log (total renal volume), total renal volume means were
signiﬁcantly different when comparing pre-operative levels to
1 year, 2 year, and 3 year followup levels (1, 2, and 3 yearmean
decrease from pre-operative level estimated at 6.8% [3.4%;
10.1%], p¼ .0002; 9.9% [5.5%; 14.0%],p< .0001; 14.8% [6.7%;
22.2%], p ¼ .0006, respectively). A signiﬁcant association be-
tween total renal volume and eGFRwas seen (increase in total
volume of 19.4% [12.8%; 26.3%] per log mL/min/1.73 m2 in-
crease of eGFR, p< .0001). Fig. 1B shows the estimatedmeans
of total renal volume (log transformed) during follow up. In a
multivariate mixed model analyzing the decrease in total vol-
ume compared with pre-operative levels (%), adjusted to a
decrease in eGFR > 20%, a greater mean decrease in renal
volume of about 3.8 [0.4; 7.3] percentage points (p ¼ .03) in
patients with a decrease in eGFR > 20% was found.
In an adjusted multivariate mixed model for log (mean
renal length), means of renal length were signiﬁcantly
different from pre-operative to 1, 2, and 3 year of follow up
(1, 2, and 3 year mean decrease from pre-operative level
estimated at 3.4% [1.3%; 5.5%], p ¼ .002; 5.1% [2.5%;
7.6%], p ¼ .0002; 6.3% [0.8%; 11.5%], p ¼ .02, respectively),
as shown in Fig. 1C. Results also showed a signiﬁcant as-
sociation between mean renal length and eGFR (increase in
mean renal length of 5.3% [2.1%; 8.7%] per log mL/min/1.73 m2 increase of eGFR, p ¼ .001). In a multivariate mixed
model analyzing the decrease in mean renal length
compared with pre-operative levels (%), adjusted to renal
impairment, no signiﬁcant decrease in mean renal length in
patients with a decrease in GFR > 20% was found.
Renal composite outcome
Intra-operative. Four intra-operative renal events were
noted, all in the FEVAR group, but without signiﬁcant dif-
ferences between device groups. One left renal artery
required an additional self expandable stent to ﬂatten a
major kink, without changes in renal function. Another
patient was found to have a kinked left renal artery that
required an additional balloon expandable stent. Despite
this re-intervention, the stent thrombosed 24 hours later
and post-operative acute renal failure with an 83% eGFR
decrease was observed. This patient died 3 months after the
procedure. Two intra-operative endoleaks were observed
on digital subtraction angiography: one type III from a left
renal artery bridging stent that resolved after re-ballooning,
and one endoleak from a failed right renal artery (RRA)
catheterization that was covered by a malpositioned
fenestrated device. An ilio-right renal bypass was performed
during the same procedure. This patient presented with
acute renal failure with a 69% decrease in eGFR.
Follow up. The 30 day renal event rate was 1.9% (4 events),
all of them in the FEVAR group. During subsequent follow
up, 23 renal events were diagnosed, including the four cases
in the ﬁrst 30 days (Table 3). Multivariate analysis did not
show a signiﬁcant inﬂuence of CKD on renal composite
outcome. The 30 day freedom from renal composite
outcome, 95% CI, was 98.6% [95.8; 99.6] and the 5 year
freedom from composite outcome was 84.5% [76.5; 89.9],
as shown in Fig. 2. During follow up, a renal related endo-
leak rate of 3.7% was observed.
Figure 1. (A) Estimated means of estimated glomerular ﬁltration rate (eGFR) (log-transformed) during follow up. (B) Estimated means of
total renal volume (log-transformed) during follow up. (C) Estimated means of mean renal length (log-transformed) during follow up.
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and 95.4% respectively. Renal occlusions were observed in
10 patients (4.4%) during follow up. Multivariate analysis
showed that the only signiﬁcant predictor of renal occlusion
was accessory renal artery fenestration (HR ¼ 7.960 [1.643;
38.573], p ¼ .01). The 30 day freedom from renal occlusion
rate was 99.5% [96.7; 99.9] and 5 year freedom from renal
occlusion rate 94.4% [89.3; 97.1].Renal related secondary interventions
During follow up 13 renal related secondary interventions
were performed. They included three early procedures
(within 30 days of the procedure), all in the FEVAR group.
Freedom from renal related secondary intervention is re-
ported in Fig. 3. The 30 day freedom and 5 year freedom
from renal related secondary intervention was 98.6 [95.7;
99.5] and 91.2 [84.2; 95.2] respectively.
In a multivariate analysis the only covariate signiﬁcantly
associated with an increased risk was procedure time
(HR ¼ 1.011 [1.005; 1.016] per minute, p ¼ .0003).Of note, one patient required device explantation 8 years
after the initial procedure because of aneurysm growth
with no endoleak identiﬁed.Renal artery angulation
An adjusted multivariate mixed model for each renal artery
(RRA and left renal artery [LRA]) angulation showed signiﬁ-
cantly different outcomes with FEVAR and BEVAR during
follow up (p < .0001 for both angulations). Following FEVAR,
means of renal artery angulation were signiﬁcantly different
when comparing pre-operative to 1, 2, and 3 year follow up
(at 3-year mean increase from pre-operative measurement
estimated at 21.34 [16.45; 26.22] for RRA; [15.77;
26.91] for LRA (p < .0001)). Following BEVAR, opposite
results were seen with a 1, 2, and 3 year mean decrease
compared with pre-operative angle measurements (21.72
[12.51; 30.93] (p < .0001) for RRA; 10.83 [3.51; 18.15]
(p ¼ .004) for LRA, at 1 year follow up).
Evolution of angulation of RRA and LRA are illustrated in
Fig. 4A,B.
Table 3. Renal events during follow up.
Patient Renal event Renal
artery
DeviceType Time to
event (months)
Pre-op
CRD
Pre-op renal
stenosis
Secondary
intervention
Renal impairment
1 Fracture Left Fen 36 No No
2 Fracture þ occlusion Left Fen 2 No No Y 57.3% GFR
3 Type I endoleak Left Bran 12 Yes No Y 48.6% GFR
4 Occlusion A Right
Left
Fen
Bran
10 No No Y 25.6% GFR
5 Kinking Right Bran 24 No No
6 Occlusion Right Bran 18 No No Y 48.2% GFR
7 Fracture Right Bran 42 Yes No
8 Dissection Right Fen 12 No No No
9 Type I endoleak Left Bran 36 No No Re-stenting No
10 Stenosis Left Fen 2 No Yes Re-stenting Y 49.4%
11 Type I endoleak
Occlusion
Left Fen 18 Yes No Embolization Y 80%
No
12 Type I endoleak
Occlusion
Left Fen 15 No No Embolization Y 69% GFR
No
13 Stenosis
Fracture
Right Bran 6
21
Yes Yes Re-stenting No
14 Occlusion Right Fen 18 Yes Yes HD
15 Occlusion Left Fen 24 hours No No Y 81% GFR
HD 21 days
16 Stenosis
Occlusion
Type I endoleak
Left
Left
Right
Fen
Sca
24
81
81
No No No
Y 28% GFR
No
17 Endoleak Left Fen 4 Yes No Re-stenting No
18 Stenosis Left Fen 6 days No No Re-stenting No
19 Fracture Left Fen 39 No No Re-stenting No
20 Type III endoleak Left Fen 24 Yes Yes Re-stenting No
21 Type I endoleak Left Fen 6 days No No Re-stenting Y 67% GFR
22 Fracture Right Bran 101 No No No
23 Kinking
Occlusion
Left Fen 12
20
No No Y 65.6% GFR
A ¼ accessory; Bran ¼ branch; Fen ¼ fenestration; GFR ¼ glomerular ﬁltration rate; HD ¼ hemodialysis; Sca ¼ scallop.
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Apart from renal artery angulation (detailed above), there
were no signiﬁcant differences in renal outcomes between
FEVAR and BEVAR at any endpoint. A signiﬁcant difference
was observed in a univariate analysis, with an increase in
renal composite endpoint in the BEVAR group (p ¼ .02),
associated with an increased relative risk of 2.724 [1.140;
6.510]. All results from the multivariate analyses to deter-
mine a device effect are reported in Table 4.DISCUSSION
Renal impairment is one of the most frequent major com-
plications after treatment of complex aneurysms. In the
current study renal outcomes including renal function (us-
ing eGFR MDRD study equation), renal volumes, and renal
lengths, and all renal events and their impact on renal
function have been analyzed. It was observed that, when
the RIFLE criteria were applied to evaluate post-operative
renal impairment, 29% of patients experienced a post-
operative decrease of eGFR (> 25% compared with base-
line), 27.2% in the FEVAR group and 37.8% in BEVAR group
(p ¼ ns). Hemodialysis was required in 5.9% of patients,
temporarily in all but one case. The new onset of dialysisrate was 0.44%. After 1 year of follow up only 40.7% of
patients that had developed post-operative ARF had
returned to eGFR baseline levels. Pre-operative CKD, pro-
cedure time and pre-operative metformin were identiﬁed
as risk factors of ARF. ARF, as well as the need for dialysis,
were correlated with an increased mortality during the ﬁrst
6 month post-operative period. No signiﬁcant differences in
renal outcomes and renal secondary interventions were
found when comparing FEVAR and BEVAR procedures, as
shown by Mastracci et al.5
Inconsistent deﬁnitions of renal dysfunction make difﬁ-
cult comparisons between different series. Initially, serum
creatinine (Scr) was used as a marker of renal dysfunction;
however, it is now considered an inaccurate marker because
of many factors impacting its level including nutritional
intake, medications, age, body mass index (BMI), weight,
sex, and race, and its concentration increasing out of
normal range only when more than half of the renal func-
tion is lost.14 Subsequently, several validated formulas used
for GFR estimation (eGFR), a more accurate measure of
renal function, have been developed,8 but different cut off
points to deﬁne renal dysfunction have been used. Katsar-
gyris et al.3 deﬁned renal impairment in their review as a
Scr increase> 30%; they reported a renal impairment rate
Figure 3. Freedom from secondary renal intervention as estimated by the multivariate Cox model.
Figure 2. Freedom from renal composite outcome as estimated by the multivariate Cox model.
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Figure 4. (A) Evolution of right renal angulation during follow up. (B) Evolution of left renal angulation during follow up. LRA ¼ left renal
artery; RRA ¼ right renal artery.
428 T. Martin-Gonzalez et al.after open repair of 18.5% associated with 3.9% of new
onset dialysis compared with 9.8% renal dysfunction and
1.5% new dialysis after FEVAR. Recent series evaluating
endovascular treatment have shown similar results. Krist-
mundsson et al.15 reported a post-operative renal impair-
ment rate of 35%, and Marzelle et al.16 18%, with 5.6% of
patients requiring dialysis. In these studies early post-
procedural renal impairment was associated with tech-
nical failure, athero-emboli and contrast nephrotoxicity; a
strong correlation between inﬂammatory and hematologi-
cal factors and renal impairment has also been described.17
Mid- and long-term renal function evolution has been
poorly evaluated in the literature after both endovascular
and open repairs. Kristmundsson15 described 22% of pa-
tients with a decrease in eGFR of more than 30% during
follow up. In comparison, this study shows a signiﬁcant
decrease in renal function during follow up; 36% of patients
presented with a decrease in eGFR> 20% after 3 years of
follow up. The later subgroup of patients experienced a
signiﬁcant volume decrease that was 3.8% higher than pa-
tients with an eGFR decrease 20%. However, mean renalTable 4. Comparison of FEVAR and BEVAR in different multivariate
analyses for every endpoint.
Endpoint multivariate analysis BEVAR effect (p)
ARF NS
Postoperative hemodialysis NS
Decrease eGFR during FU .01
Decrease total renal volume during FU NS
Decrease mean length during FU NS
Renal composite outcome NS
Renal related endoleak NS
Renal occlusion NS
Renal related secondary intervention NS
Death NS
ARF ¼ acute renal failure; eGFR ¼ estimated glomerular ﬁltration
rate; FU ¼ follow up; NS ¼ not signiﬁcant.length decrease was similar in both groups and thus seems
not to be an accurate or early marker of renal impairment.
It seems unlikely that others will adopt measurement of
renal volume based on our ﬁndings. Although our results
may not change follow up protocols, it was interesting to
show a continuous diminution in total renal volume during
follow up correlated with an eGFR decrease. The clinical
relevance of this ﬁnding has yet to be ascertained.
According to Fillinger’s reporting standards,13 the tech-
nical success rate in this study was 95.5%. These results are
similar to the published literature with technical success
rates ranging from 82.2% to 100%.11,16,18e21 Analysis of
renal events and renal patency and its relation to renal
function have been performed to evaluate durability of
these devices and to suggest design of branches or fenes-
trations in relation to aneurysm extent and vessel orienta-
tion. Durability of open repair, mid- and long-term renal
impairment, and secondary procedures associated with
these procedures have been poorly described in the liter-
ature. In his review, Katsargyris3 mentioned only three
studies that evaluated renal patency of 88% during follow
up. The good results obtained in this study conﬁrm the
favorable outcomes associated with endovascular repair.
This study reports 30 day and follow up renal patency rates
of 97.7% and 95.4% respectively; the 5 year freedom from
renal occlusion and freedom from secondary renal inter-
vention rates were 94.4% and 91.2% respectively. These
data are similar to the global patency rates of 93.5%
described by Verhoeven22 or 96% described by Krist-
mundsson.15 Consequently, it seems probable that target
vessel occlusion is more frequently a consequence of
technical errors during endograft design or implantation
than structural fatigue or neointimal hyperplasia. Delayed
renal impairment is largely the result of mechanical device
failure. In addition, the type of bridging stent, the choice
between fenestrated or branched devices, and the target
vessel anatomy have been analyzed in previous studies to
Renal outcomes following FEVAR and BEVAR 429determine their involvement in target vessel patency.
Mohabbat et al.11 have shown a greater rate of occlusion
with uncovered stents. Early fenestrated devices were
performed with uncovered stents, but since 2006 branched
and fenestrated devices have been performed with covered
stents. The authors’ experience started in 2004, and almost
all procedures were performed with covered stents. To
assess device durability a rigorous follow up is mandatory.
Yearly duplex surveillance is required in addition to CT.
Duplex provides a hemodynamic evaluation of bridging
stents and target vessels, while CT scans will verify device
integrity and positioning.
Renal artery angulation and movements with breathing
or anatomy modiﬁcation after stent implantation have an
impact on renal outcomes. In 2005, Draney et al.23 reported
that the right renal artery had greater curvature than the
left, as well as a greater change in curvature due to the
increased degree of right kidney motion. This increase in
curvature and motion may apply more force and stress on
stents implanted in this region. A model study from Geor-
gakarakos24 has analyzed multiple values of take off angle
between the renal stent and the endograft. The narrow
transitional zone between the bridging stent and the
endograft presented the highest stress value correlated
with endothelial damage and stent fatigue, and induced
local thrombogenic activity compromising lumen patency.
This study showed that both renal arteries had increased
renal angulation after the procedure, tending to the
perpendicular of centerline ﬂow in fenestrated devices.
However, with branched devices, left and right artery
angulation presented a decrease, trending to the centerline
ﬂow. These changes in renal artery angulation have not
been identiﬁed as risk factors for renal occlusion or for renal
composite outcomes, but further study must be undertaken
to determine the importance of these changes.
Endoleaks related to renal bridging stents were seen in
3.37% of patients. This may be from material fatigue and
stent fracture responsible for type III endoleaks, and from
aneurysm disease evolution with component separation
responsible for type III endoleaks or with loss of sealing
zone responsible for type I endoleaks. Aortic aneurysm is a
global disease involving the whole aorta. Device planning is
one aspect that is considered integral to long-term dura-
bility. It is important not to compromise the landing zone
(establishing proximal landing zones in a region of> 2 cm
parallel walled and thrombus free aorta and of minimal
tortuosity) regardless of the number of fenestrations or
branches involved. To minimize the risk of component
separation, it is also important to plan for at least 75 mm of
overlap.Study limitations
This is a retrospective study that included a limited number
of patients. Recent experience was excluded because of a
desire to ensure that complete 12 month follow up was
observed in all cases. This means that the patients described
in this paper were not treated in a hybrid operating roomand thus did not undergo completion cone beam CT to
assess technical success. This latter examination may reduce
the need for early secondary re-interventions.
In a recent study evaluating the natural rate of decline in
renal function with age, the authors reported a decline in
eGFR of 1.15 mL/min/1.73 m2 every year in a pop-
ulation> 50 years with a baseline clearance above 90 mL/
min/1.73 m2.25 Another study in a healthy population> 65
year olds observed a decline of eGFR of 2.37 mL/min/
1.73 m2 every year.(26) Both studies show that even in
healthy populations renal function undergoes a decrease
with age; this decrease is probably increased in a vascular
patient cohort. It is thus difﬁcult to estimate the inﬂuence
of mechanical factors in the decline of renal function in the
patients enrolled in this study. In addition, without a control
group, it is difﬁcult to claim that the reduction in renal
volume was related to the intervention.
Reproducibility of angulation measures can also be
considered as a limitation. A study performed with the goal
of quantifying the amount of variability for inter-observer
assessment of aortic neck length and angulation from CTs
resulted in highly inconsistent measurements.27 While slight
variations in the measure of renal angulation may exist due
to the use of a single reader, inter-observer error was elim-
inated, as it had been accomplished in the Conway study.10
Another limitation of this study was 12 unexplained
deaths during follow up. Although patients appeared to
have no device related complications at their last known
follow up, without an accurate assessment of cause of
death it is unclear how to interpret mortality in these 12
patients.
CONCLUSION
FEVAR and BEVAR are durable options for the treatment of
complex aortic aneurysms and are associated with low renal
morbidity, without differences between these devices. Post-
operative ARF increases mortality at 6 months. The clinical
impact of decreasing renal volume over time in these pa-
tients is yet to be fully understood.
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